Recombinant activated factor VII (rFVIIa, NovoSeven®)

Journal of Association of Physicians of India

Volumn 53, Issue AUG, 2005, Pages 717-720

  Agarwal, M B ^a   Patnaik, M ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; DRUG EFFECT; HEMOSTASIS; HUMAN; REVIEW;

BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; FACTOR VII; FACTOR VII DEFICIENCY; HEMOSTASIS; HUMANS; RECOMBINANT PROTEINS;

EID: 24644465093     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective randomized trial of two doses of r-FVIIa in Hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80: 773-78.
2. Maick BG. Treatment of factor VII inhibitors: products and strategies. Semen Thromb Hemost 1993;19:13-24.
3. Nillson IM, Berntop E, Freiburghas C. Treatment of patients with Factor VII and IX inhibitors. Thromb Haemost 1993;70:56-59.
4. Bray G, Gomperts ED, Courter S, Gruppo R, Gordon EM, et al. A muticenter study of recombinant factor VIII: safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. The recombinate study group. Blood 1994;83:2428-2435.
5. Hay CRM, Lozier JN, Lee CA, et al. Porcine factor VIII inpatients with congenital hemophilia and inhibitors: efficacy, patient selection and side effects. Semin Hematol 1994;31:20-25
6. Rao LVM, Rappaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of coagulation. Proc Natl Acad Sci USA 1988;85:6687-91.
7. Brinkhous KM, Hender U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the haemostatic defect in dogs with hemophilia A, B and von-Willebrands disease. Proc Natl Acad Sci USA 1989;86:1382-6.
8. Lindley CM, Sawyer WT, Maick BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VII a. Clin Pharmacol Ther 1994;55:638-48.
9. Hedner U, Glazer S. Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am 1992;6:1035-46.
10. Roberts H. Clinical experience with recombinant factor VIIa (Novo Seven): summary of efficacy and safety. Hemophilia 1996;2:63.
11. Molskov BR. Recombinant factor VII a in joint and muscle bleeding episodes. Haemostasis 1996;26:131-4.
12. NovoSeven® - recombinant factor VIIa Novo Nordisk's EU Package Insert
13. Mariani G, Testa MG, Piolantonio TD, Molskov RB, Hedner U. Use of recombinant activated FVIIa in the treatment of congenital factor VII deficiencies. Vox Sang 1999;77:131-36.
14. d'Oiron R, Menart C, Trzeciak MC, et al. Use of rFVIIa in 3 patients with inherited type 1 Glanzmanns Thrombasthenia undergoing invasive procedures. Thromb Haemost 2000;83:644-7.
15. Mauricio L, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002;28: S241-247.
16. Roberts H. Safety of treatment with NovoSeven® . Blood Line Reviews 2001;1:18-19.
17. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
18. Rossaint R, Boffard K, Warren B, et al. Decreased Transfusion Utilization Using Recombinant Factor VIIa as an adjunct in Trauma. Poster Presentation at European Society of Intensive Care Medicine (ESICM), 10-13 Oct 2004,Berlin,Germany.
19. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71:402-5
20. Gielen-Wijiffels SEMJ, van Mook, van der Geest, et al. Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med 2004;30:1232-34.
21. Mayer SA, Brun NC, Begtrup K, Broderick J, et al. Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. NEJM 2005;352:777-85.
22. Erhardsten E. Pharmacokinetics of recombinant activated factor VIIa (rFVIIa). Semin Thromb 2000;26385-91.
23. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996;26(Suppl 1):102-8.
24. CPT George S. Midla. Recombinant factor VIIa and its clinical applications. Army Medical Department Journal PB 8-04-7/8/9 Jul/Aug/Sep.
25. Dutton RP, Hess JR, Thomas MS. Recombinant Factor VIIa for Control of Hemorrhage: Early Experience in Critically Ill Trauma Patients. J Clin Anaesth 2003;15:184-88.
26. Erhardsten E. Ongoing NovoSeven® trials. Intensive Care Med 2002; 28: S248-55.
27. Eikelboom JW, Robert B, David B, et al. recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003;14:713-17.